Pharmanex is a nutritional-supplement and wellness brand founded in 1994 and acquired by Nu Skin Enterprises in 1998. The company was originally built around applying pharmaceutical-style research, quality control, and natural-products science to dietary supplements. After becoming part of Nu Skin, Pharmanex shifted from broader retail distribution into Nu Skin's direct-selling channel and became one of Nu Skin's core product brands.
Pharmanex products center on nutritional supplements, wellness systems, healthy-aging formulas, weight-management products, antioxidant-support products, targeted nutrition, and related wellness technology. Current Nu Skin materials describe Pharmanex as the company's wellness brand, with products such as LifePak, ageLOC wellness products, TRME, Beauty Focus, and related nutritional formulas sold through Nu Skin's global ecommerce and direct-selling structure. Nu Skin reported $689.1 million in 2025 wellness-product revenue, representing 46.4% of total company revenue.
Pharmanex operates through Nu Skin's direct-selling and affiliate model rather than as a separate standalone distributor opportunity. Nu Skin Brand Affiliates promote Nu Skin and Pharmanex products through person-to-person marketing, social sharing, customer referrals, ecommerce tools, retail resale, and team-based product-sales compensation. Nu Skin's current U.S. disclosure states that Brand Affiliates can earn retail markup on product resales and sales compensation from product sales by themselves and others on their team. In 2025, Nu Skin paid approximately $84.107 million in U.S. Brand Affiliate sales compensation, with an average of 39,211 monthly active U.S. Brand Affiliates and 26.67% earning a sales-compensation payment in an average month.
Pharmanex remains active as part of Nu Skin Enterprises. The Pharmanex brand is no longer a separate independent MLM company, but it continues as Nu Skin's legacy wellness and nutrition brand within a publicly traded global direct-selling company. Nu Skin remains active in approximately 50 markets and continues to sell Pharmanex-branded nutrition products through its Brand Affiliate and customer channels.
Pharmanex's regulatory history includes the Cholestin red-yeast-rice case, one of the better-known FDA dietary-supplement disputes of the late 1990s and early 2000s. FDA advised Pharmanex in 1997 that Cholestin was a drug that could not be marketed without FDA approval, because the product contained mevinolin/lovastatin, chemically identical to the active ingredient in Merck's prescription drug Mevacor. Pharmanex challenged FDA's position and initially won in district court, but the Tenth Circuit reversed in 2000 and held that FDA could regulate active ingredients as well as finished drug products under the relevant dietary-supplement exclusion. Nu Skin's broader regulatory history also includes FTC settlements before the Pharmanex acquisition, including a 1997 $1.5 million civil penalty involving fat-loss and supplement claims.